Clearside Biomedical, Inc. (CLSDQ) vs Virax Biolabs Group Limited (VRAX)

Clearside Biomedical, Inc. and Virax Biolabs Group Limited are both Biotechnology companies. Clearside Biomedical, Inc. and Virax Biolabs Group Limited are of similar size ($2.2M and $2.2M). Virax Biolabs Group Limited has the higher net margin (0.00% vs −780.9%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, Virax Biolabs Group Limited leads on 7 and Clearside Biomedical, Inc. on 5.

Valuation

Metric CLSDQ VRAX Biotechnology median
P/E n/m n/m 8.50
P/S 0.39 n/m 9.71
P/B n/m n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.18 0.86 0.64
EV/Sales (1.24) n/m 9.21
Earnings yield (2,075.24%) (367.59%) (33.15%)
Free cash flow yield (1,661.90%) 0.00% (25.50%)

Profitability

Metric CLSDQ VRAX Biotechnology median
Gross margin 92.55% — 65.16%
Operating margin (689.76%) — 0.00%
Net margin (780.93%) 0.00% 0.00%
Free cash flow margin (653.23%) 0.00% 0.00%
Return on equity 58.59% 0.00% (56.36%)
Return on assets (127.43%) 0.00% (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CLSDQ VRAX Biotechnology median
Revenue growth (TTM) (56.78%) — 6.02%
EPS growth (last fiscal year) 11.32% 68.79% 30.26%
Revenue growth, 5-year CAGR (5.20%) (36.88%) 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CLSDQ VRAX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 2.98 9.97 4.72
Net debt to EBITDA 0.69 1.08 0.96

Dividend

Metric CLSDQ VRAX Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric CLSDQ VRAX Biotechnology median
Market cap 2.15m 2.18m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack